Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1 -Mutated or KMT2A -Rearranged AML

PURPOSE: ). METHODS: (ClinicalTrials.gov identifier: NCT03013998). RESULTS: : 78%). No patient had refractory disease after 1-2 cycles of treatment. The median time to first response was 28 days, and 84% of responders achieved remission within the first cycle. All 37 patients evaluated had no evidence of measurable residual disease by a centralized flow cytometry assay. CONCLUSION: AML, the combination of azacitidine, venetoclax, and revumenib was able to be safely administered with high rates of CR and clinical activity.